Centanafadine (
INN
Inns are generally establishments or buildings where travelers can seek lodging, and usually, food and drink. Inns are typically located in the country or along a highway; before the advent of motorized transportation they also provided accommo ...
) (former developmental code name EB-1020) is a
serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that began its
development
Development or developing may refer to:
Arts
*Development hell, when a project is stuck in development
*Filmmaking, development phase, including finance and budgeting
*Development (music), the process thematic material is reshaped
* Photograph ...
with
Euthymics Bioscience after they acquired
DOV Pharmaceutical
DOV Pharmaceutical was a biotechnology company that focused on therapies primarily for central nervous system conditions. It was founded in 1995 by former employees of American Cyanamid (which was acquired by Wyeth in 1994), and in 1998 it in-lic ...
. It was developed as a treatment for
attention-deficit hyperactivity disorder
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterised by excessive amounts of inattention, hyperactivity, and impulsivity that are pervasive, impairing in multiple contexts, and otherwise age-inappr ...
(ADHD) and inhibits the
reuptake
Reuptake is the reabsorption of a neurotransmitter by a neurotransmitter transporter located along the plasma membrane of an axon terminal (i.e., the Synapse, pre-synaptic neuron at a synapse) or glial cell after it has performed its function of ...
of
norepinephrine
Norepinephrine (NE), also called noradrenaline (NA) or noradrenalin, is an organic chemical in the catecholamine family that functions in the brain and body as both a hormone and neurotransmitter. The name "noradrenaline" (from Latin '' ad' ...
,
dopamine, and
serotonin with a ratio of 1:6:14, respectively.
In 2011,
Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance.
In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine. As of January 2018, Otsuka's pipeline indicates it is in Phase III clinical trials.
See also
*
Amitifadine
*
Bicifadine
*
Dasotraline
*
DOV-216,303
*
Tesofensine
References
External links
Centanafadine - AdisInsight
2-Naphthyl compounds
Serotonin–norepinephrine–dopamine reuptake inhibitors
Stimulants
Nitrogen heterocycles
Cyclopropanes
{{nervous-system-drug-stub